Scibase

SciBase's mission is to pioneer prediction and prevention in skin health by empowering clinicians with advanced diagnostic tools. Its key achievement is the development and commercialization of the Nevisense platform, which has gained regulatory approval for melanoma and keratinocyte cancer detection based on robust clinical evidence. The company's strategy focuses on expanding the platform's applications, scaling commercial operations in key markets, and leveraging its unique EIS+AI technology to become a standard of care in dermatological diagnostics.

The Nevisense platform integrates patented Electrical Impedance Spectroscopy (EIS), which measures the biophysical properties of skin tissue, with proprietary Augmented Intelligence (AI) algorithms trained on extensive clinical data to assist in diagnostic decision-making at the point of care.

SciBase competes with companies like Castle Biosciences (genomic tests) and DermTech (genomic patch) but is differentiated by its real-time, point-of-care EIS+AI platform that provides immediate results. Its primary competition is the entrenched standard of care: visual inspection with dermoscopy.